Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer

Current Medical Research and Opinion ◽

10.1185/03007995.2015.1062358 ◽

2015 ◽

Vol 31 (8) ◽

pp. 1573-1582 ◽

Author(s):

Nanxin Li ◽

Yanni Hao ◽

Jipan Xie ◽

Peggy L. Lin ◽

Zhou Zhou ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Associated Factors ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Menopausal Women ◽

Epidermal Growth ◽

Post Menopausal

Download Full-text

PCN246 BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2- NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK

Value in Health ◽

10.1016/j.jval.2019.09.441 ◽

2019 ◽

Vol 22 ◽

pp. S483

Author(s):

A.H. Møller ◽

L. Oddershede

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Budget Impact ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Menopausal Women ◽

Epidermal Growth ◽

Post Menopausal

Download Full-text

Healthcare medical costs among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) managed with systemic therapy following CDK 4/6 inhibitor (CDKi) in the real-world setting.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1067 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1067-1067

Author(s):

Nicole Princic ◽

Derek Tang ◽

Aditya Bardia ◽

David Smith ◽

William M. Johnson ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Real World Setting ◽

Menopausal Women ◽

Epidermal Growth ◽

Post Menopausal

Download Full-text

Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)

European Journal of Cancer ◽

10.1016/j.ejca.2021.05.025 ◽

2021 ◽

Vol 153 ◽

pp. 223-233

Author(s):

Volkmar Mueller ◽

Andrew Wardley ◽

Elisavet Paplomata ◽

Erika Hamilton ◽

Amelia Zelnak ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Epidermal Growth

Download Full-text

Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India

ecancermedicalscience ◽

10.3332/ecancer.2021.1207 ◽

2021 ◽

Vol 15 ◽

Author(s):

Anjana Joel ◽

Josh Thomas Georgy ◽

Divya Bala Thumaty ◽

Ajoy Oommen John ◽

Raju Titus Chacko ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Neoadjuvant Chemotherapy ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Patterns Of Use ◽

Epidermal Growth

Download Full-text

Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2–negative Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.09.007 ◽

2020 ◽

Vol 20 (2) ◽

pp. 160-167

Author(s):

John Smith ◽

Amy Irwin ◽

Lori Jensen ◽

Karen Tedesco ◽

Soamnauth Misir ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Eribulin Mesylate ◽

Epidermal Growth

Download Full-text

Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis

Annals of Oncology ◽

10.1093/annonc/mdw337.21 ◽

2016 ◽

Vol 27 ◽

pp. iv65

Author(s):

L. Pizzuti ◽

I. Sperduti ◽

A. Michelotti ◽

C. Omarini ◽

T. Gamucci ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Epidermal Growth

Download Full-text

Chromosome 17 Polysomy without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared with Paclitaxel in Metastatic Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-1643 ◽

2010 ◽

Vol 16 (4) ◽

pp. 1281-1288 ◽

Author(s):

L. Downey ◽

R. B. Livingston ◽

M. Koehler ◽

M. Arbushites ◽

L. Williams ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Chromosome 17 ◽

Human Epidermal Growth Factor ◽

Epidermal Growth

Download Full-text

Efficacy and safety of bevacizumab in the treatment of human epidermal growth factor receptor type 2 negative metastatic breast cancer: About a large series in moroccan population

Indian Journal of Cancer ◽

10.4103/0019-509x.146779 ◽

2014 ◽

Vol 51 (3) ◽

pp. 272 ◽

Author(s):

N Majid ◽

S Boutayeb ◽

H Errihani

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Epidermal Growth

Download Full-text

Phase II study of weekly administration of docetaxel (D) in combination with the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in metastatic breast cancer (MBC).

10.1158/0008-5472.sabcs-3124 ◽

2009 ◽

Author(s):

H Kaur ◽

P Silverman ◽

D Singh ◽

P Fu ◽

R Farag ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Egfr Inhibitor ◽

Weekly Administration ◽

Epidermal Growth

Download Full-text

Abstract P1-13-06: Impact of visceral metastases on treatment patterns for hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC)

10.1158/1538-7445.sabcs14-p1-13-06 ◽

2015 ◽

Author(s):

James Signorovitch ◽

Jenny Wang ◽

Ruo-Ding Tan ◽

Darren Thomason ◽

Andrew Kageleiry ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Treatment Patterns ◽

Hormone Receptor Positive ◽

Visceral Metastases ◽

Epidermal Growth

Download Full-text